Lee’s Pharmaceutical Holdings (0950.HK) presentation began with an overview of the Q3 2018
financial results, which had a finalised revenue of HK$299.2m. They noted revenue of HK$866.9m
for 9-months ended September 30, 2018, which is a 15.6% increase from 2017. Officials indicated
that they were investing heavily in R&D for future returns as of 9-months in 2018 R&D expenses
where at an all-time high of HK$95.8m, whilst the profit margin was held at 66.1%. The team
noted that they have 7 products in Phase III in multiple disease categories with large market sizes
including cardiovascular, oncology and ophthalmology. Lee officials then focused on
manufacturing sites where they confirmed that the construction for the biologics drug substance
and liposome production line had been completed at the Hefei manufacturing site. Additionally,
they addressed the manufacturing licence for the mono-dose line at Guangzhou that they
obtained in September 2018 and the cytotoxic capsules licence gained in October 2018.
Lee’s Pharmaceuticals then briefly described their prospects for 2019, which included the
enhancement of their sales team to maintain the strong sales growth momentum observed over
the past year. They also aim to increase their R&D expenditure and progressively isolate R&D
activities in oncology and ophthalmology from their core revenue stream. Pharmaceuticals
concluded with an explanation of the potential challenges in 2019 and how they plan to
overcome them. The China Health Commission aims to set up a national auxiliary drug list, which
they will closely monitor. Officials hinted that they are in a favourable position as their products
are not under the auxiliary drug category.
financial results, which had a finalised revenue of HK$299.2m. They noted revenue of HK$866.9m
for 9-months ended September 30, 2018, which is a 15.6% increase from 2017. Officials indicated
that they were investing heavily in R&D for future returns as of 9-months in 2018 R&D expenses
where at an all-time high of HK$95.8m, whilst the profit margin was held at 66.1%. The team
noted that they have 7 products in Phase III in multiple disease categories with large market sizes
including cardiovascular, oncology and ophthalmology. Lee officials then focused on
manufacturing sites where they confirmed that the construction for the biologics drug substance
and liposome production line had been completed at the Hefei manufacturing site. Additionally,
they addressed the manufacturing licence for the mono-dose line at Guangzhou that they
obtained in September 2018 and the cytotoxic capsules licence gained in October 2018.
Lee’s Pharmaceuticals then briefly described their prospects for 2019, which included the
enhancement of their sales team to maintain the strong sales growth momentum observed over
the past year. They also aim to increase their R&D expenditure and progressively isolate R&D
activities in oncology and ophthalmology from their core revenue stream. Pharmaceuticals
concluded with an explanation of the potential challenges in 2019 and how they plan to
overcome them. The China Health Commission aims to set up a national auxiliary drug list, which
they will closely monitor. Officials hinted that they are in a favourable position as their products
are not under the auxiliary drug category.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.